Cargando…
Fresh from the biotech pipeline: too much, too fast?
2021 witnessed regulators’ continued push to accelerate approvals and adjust to COVID-19, but has the pendulum swung too far in drug makers’ favor?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group US
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802986/ https://www.ncbi.nlm.nih.gov/pubmed/35102293 http://dx.doi.org/10.1038/s41587-022-01208-2 |